Compare ATRC & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATRC | MPLT |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2005 | 2025 |
| Metric | ATRC | MPLT |
|---|---|---|
| Price | $47.49 | $11.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $51.17 | $32.67 |
| AVG Volume (30 Days) | 868.6K | ★ 1.3M |
| Earning Date | 05-05-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 74.74 | ★ 82.39 |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $201,630,000.00 | N/A |
| Revenue This Year | $15.27 | N/A |
| Revenue Next Year | $12.21 | N/A |
| P/E Ratio | $264.50 | ★ N/A |
| Revenue Growth | ★ 15.40 | N/A |
| 52 Week Low | $25.36 | $9.10 |
| 52 Week High | $47.98 | $40.43 |
| Indicator | ATRC | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 82.50 | 29.52 |
| Support Level | $26.47 | $10.83 |
| Resistance Level | N/A | $20.20 |
| Average True Range (ATR) | 1.61 | 0.98 |
| MACD | 0.45 | 0.44 |
| Stochastic Oscillator | 94.70 | 7.22 |
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.